Tag: Januvia
-
Januvia, Onglyza, Other Diabetes Drugs In DPP-4 Inhibitor Class Significantly Increase Risk Of Crohn’s Disease (CD)
But Same Medical Study Finds That DPP-4 Inhibitors Do Not Increase Risk Of Inflammatory Bowel Disease (IBD) (Posted by Tom Lamb at DrugInjuryWatch.com) Back in March 2018 we wrote this report, “Januvia,…
-
Diabetes Drugs In DPP-4 Inhibitor Class Associated With Almost Two-Times Increased Risk Of Cholangiocarcinoma
Medical Researchers Finding This Rare But Highly Fatal Cancer Call For More Investigation Into New Possible Drug Side Effect (Posted by Tom Lamb at DrugInjuryWatch.com) A recent medical study shows that the…
-
DPP-4 Diabetes Drug Side Effects Include Heart Attacks And Strokes As Well As Heart Failure
Onglyza, Nesina, Januvia, and Tradjenta Are Included In This Popular Class Of Type-2 Diabetes Medications (Posted by Tom Lamb at DrugInjuryWatch.com) In April 2016 the FDA took regulatory action by mandating label…
-
Januvia, Onglyza, And Certain Other Diabetes Drugs Linked To Inflammatory Bowel Disease (IBD)
New Study Finds Overall 75% Increase In Risk Of IBD, And Association Peaked Between 3 And 4 Years Of Use (Posted by Tom Lamb at DrugInjuryWatch.com) According to an observational study published…
-
Four Distinct Diabetes Drugs MDL Cases: Byetta / Januvia / Victoza; Onglyza / Kombiglyze; Invokana; Farxiga
Current Number Of Drug Injury Lawsuits Filed In Each Of These Ongoing Federal Court MDL Cases: February 2018 JPML Report (Posted by Tom Lamb at DrugInjuryWatch.com) At the present time there are…
-
Diet Drug Saxenda May Increase Pancreatic Cancer Risks For Patients Only Wanting Weight Loss
Saxenda Dose Contains Twice As Much Liraglutide As Diabetes Medicine Victoza, Also Linked To Malignancy In Pancreas (Posted by Tom Lamb at DrugInjuryWatch.com) In 2014, the FDA approved Saxenda (liraglutide) for the…
-
Potential Safety Signal: Rhabdomyolysis May Be Linked To Onglyza, Nesina, Januvia, And Other Diabetes Drugs
FDA Was Already Investigating The Dipeptidyl Peptidase IV (DPP-IV) Inhibitor Class Of Diabetes Drugs For Kidney Or Renal Failure (Posted by Tom Lamb at DrugInjuryWatch.com) According to a new FDA quarterly report,…
-
There Is Continuing Concern About Whether Victoza Is Associated With Pancreatic Cancer As A Possible Side Effect
The FDA Briefing Materials For A June 2017 Advisory Committee Meeting On Victoza Include A Discussion Of This Safety Issue (Posted by Tom Lamb at DrugInjuryWatch.com) On June 20, 2017 there will…
-
Onglyza, Nesina, And Similar Diabetes Drugs Get FDA Drug Safety Warnings About Risk Of Heart Failure Side Effect
Set Of Newer Diabetes Medications Containing Saxagliptin And Alogliptin Also Being Investigated By FDA For Increased Risk Of Renal Failure (Posted by Tom Lamb at DrugInjuryWatch.com) On April 5, 2016 the FDA…
-
Onglyza, Nesina, And Similar Diabetes Drugs Get FDA Drug Safety Warnings About Risk Of Heart Failure Side Effect
Set Of Newer Diabetes Medications Containing Saxagliptin And Alogliptin Also Being Investigated By FDA For Increased Risk Of Renal Failure (Posted by Tom Lamb at DrugInjuryWatch.com) On April 5, 2016 the FDA…